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Abstracts
CONCLUSION: Existing epidemiological data can pro-
vide tailored estimates of concrete benefits resulting from
improving the quality of anticoagulation.
CV2
A SIX YEAR FOLLOW-UP STUDY OF THE 
RELATIONSHIP BETWEEN MORTALITY, 
HOSPITALISATION AND ADHERENCE TO 
STATIN TREATMENT AFTER FIRST 
MYOCARDIAL INFARCTION
Wei L, Wang J, Davey P, MacDonald T
MEMO, University of Dundee, Dundee, UK
OBJECTIVE: To measure adherence to statins by pa-
tients treated for secondary prevention after myocardial
infarction and to estimate the effect of adherence on out-
come.
METHODS: We used a cohort design in the population
of Tayside, Scotland. Patients who experienced their first
MI between January 1990 and November 1995 were
identified from hospital discharge data. We used two out-
comes: mortality from any cause; hospitalization for re-
current MI. Adherence to statins was calculated as the
number of days for which statins were supplied divided
by the total number of days in the study for each patient.
Results were adjusted for age, sex, deprivation (as mea-
sured by the Carstairs code), serum cholesterol level, dia-
betes mellitus, cardiovascular drugs and other hospital-
ization using a Cox regression model.
RESULTS: Of 5590 patients enrolled in the cohort 1299
(23.2%) died during the follow-up period and 717
(12.8%) experienced at least one further MI. Only 7.7%
of patients used statins, and in comparison with non-us-
ers, these patients had more cardiovascular risk factors.
Compared to those not using statins, the adjusted relative
risk of mortality (95% CI) by quintiles of adherence was
0.65 (0.24–1.80) for the worst adherence quintile, 0.46
(0.06–3.43) for the second, 1.03 (0.37–2.88) for the
third, 0.19 (0.03–1.37) for the fourth, and 0.20 (0.09–
0.47) for the best adherence quintile. The adjusted rela-
tive risks of readmission by quintiles of adherence were
0.65 (0.24–1.79) for the worst adherence quintile, 0.47
(0.06–3.51) for the second, 1.05 (0.37–2.94) for the
third, 0.20 (0.03–1.41) for the fourth, and 0.21 (0.09–
0.48) for the best adherence quintile.
CONCLUSIONS: Statins were used infrequently and use
was a marker of cardiovascular risk. Despite such confound-
ing by indication, good adherence to treatment was associ-
ated with lower risks of further MI and lower mortality.
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OBJECTIVE: The IMPRESS clinical trial randomized pa-
tients with congestive heart failure to a daily regimen of
either omapatrilat or lisinopril. At 24 weeks, patients
randomized to omapatrilat had a significant reduction in
the primary endpoint of death, hospitalization, or discon-
tinuation of study drug for worsening heart failure (p 
.035) and fewer cardiac events (p  .04). This study
sought to determine the economic consequences of the
omapatrilat patient’s lower event rates.
METHODS: Economic outcomes were assessed in terms
of hospitalization events and their medical costs. Hospi-
tal event information was obtained via serious adverse
event forms, and hospital costs were evaluated by assign-
ing each hospitalization a DRG-based average cost for
physician and hospital services. Emergency room visits
for worsening heart failure were assigned costs equivalent
to those at Duke University Medical Center. All costs
were expressed in 1998 US dollars. Drug costs were not
assessed.
RESULTS: Patients in the omapatrilat (n  289) and lisi-
nopril (n  284) arms were evenly matched with regard
to baseline characteristics: age (both 64 years); NYHA
class III or IV heart failure (36% versus 38%); ejection
fraction (both 28%). There was no difference between study
arms in all-cause mortality. However, there was a trend to-
ward a greater number of all-cause hospitalizations in
the lisinopril versus omapatrilat patients (0.275 versus
0.215, p  .07). Differences in cardiac hospitalizations be-
tween lisinopril and omapatrilat were significant (0.208
versus 0.145, p  .03). There was a trend toward re-
duced medical costs at 24 weeks follow-up in omapatri-
lat-treated patients (US$1930 versus US$2002, p  .09).
Considering only cardiac medical costs, this trend toward
reduced medical costs became significant (US$1240 ver-
sus US$1442, p  .03).
CONCLUSIONS: In the first study to compare economic
outcomes in congestive heart failure patients treated with
omapatrilat and lisinopril, we found fewer hospitaliza-
tions and lower medical costs for omapatrilat patients at
24 weeks.
COST ESTIMATION
CE1
IMPACT OF CENSORED COST DATA ON THE 
OUTCOMES OF ECONOMIC EVALUATIONS
Oostenbrink JB, Al MJ, Rutten-van Mölken MM
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OBJECTIVE: Patients in a clinical trial who withdraw
before the scheduled end date are a serious problem in
economic evaluations. The method to deal with data
from these patients can have important impact on out-
